
About Artiva:
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. Our mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases. We aim to develop therapies that patients and physicians can utilize in a community setting. Our lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). We believe the compelling cell-killing properties of NK cells, when combined with mAbs for targeting, create an opportunity to generate potentially transformative therapies.
For more information, visit www.artivabio.com
We’re seeking a QA Document Control professional with 3+ years of GMP/regulatory experience to manage:
Overview
This position is responsible for supporting Quality Assurance Operations activities at Artiva, with primary responsibilities for document control, records management, training management, and controlled labeling utilizing Artiva’s electronic Quality Management System. The role supports compliant and efficient quality system operations by ensuring controlled documents, training records, labeling, logbooks, and related quality records are accurate, current, traceable, and maintained in accordance with applicable procedures, regulatory requirements, and company standards.
Duties and Responsibilities:
Join us. Make an impact in a fast-growing company.
Affirmative Action/EEO statement
Artiva Biotherapeutics is an equal employment opportunity employer.
Please no agencies

Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.